Compare Merck & Co., Inc. (MRK) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Victoria's Secret & Co — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Victoria's Secret & Co trades at $87.09 (market cap $6.95B). The key difference: Merck & Co., Inc. is far larger — about 44.2× Victoria's Secret & Co's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Victoria's Secret & Co pays none. Which is the better fit depends on your goals.
| MRK | VSXY | |
|---|---|---|
Market Cap | $307.25B | $6.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $129.52 | $88.50 |
52-Week Low | $77.60 | $18.72 |
Enterprise Value | $350.66B | $9.59B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Victoria's Secret (VSXY) trades at $87.09, up 6.92% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows improving fundamentals with revenue stabilizing at $6.23B in 2025 and net income recovering to $165M. Analyst consensus is bullish with a $88.56 price target, and institutional interest is growing, evidenced by Bessemer Group's increased stake in Q1 2026.
The outlook remains positive driven by international expansion, particularly in China, and product innovation. Risks include competitive pressures in retail and margin volatility. With no sell ratings from analysts and strong shareholder support for management, VSXY presents a growth opportunity, though investors should monitor execution on guidance and macroeconomic impacts on consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
